Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lexicon Pharmaceuticals ( (LXRX) ) just unveiled an announcement.
On January 29, 2026, Lexicon Pharmaceuticals entered into an underwriting agreement for a public offering of 32 million common shares at $1.30 per share and, on February 2, 2026, closed a concurrent private placement with affiliates of its largest shareholder, Invus, involving 22.4 million common shares and multiple tranches of Series B convertible preferred stock. The transactions, together priced at approximately $94.6 million in gross proceeds, strengthen Lexicon’s capital position to fund research and development and general corporate purposes, while also reinforcing Invus’s strategic stake and leading to amendments to Lexicon’s charter, including a planned increase in authorized common shares and the creation of Series B convertible preferred stock that will automatically convert into common stock once specified corporate and regulatory approvals are obtained.
The most recent analyst rating on (LXRX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.
Spark’s Take on LXRX Stock
According to Spark, TipRanks’ AI Analyst, LXRX is a Neutral.
The score is primarily constrained by weak financial quality—ongoing losses and negative/declining cash flows—despite strong revenue growth. Technicals are also soft with the stock below key short- and mid-term moving averages. Offsetting these, management’s earnings call commentary and a new financing event support continued pipeline execution, but valuation remains challenged due to lack of profitability.
To see Spark’s full report on LXRX stock, click here.
More about Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing pioneering medicines, with a pipeline of drug candidates in discovery, clinical and preclinical development targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolism and other indications.
Average Trading Volume: 2,397,144
Technical Sentiment Signal: Sell
Current Market Cap: $421.5M
See more insights into LXRX stock on TipRanks’ Stock Analysis page.